Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients

Annals of Hematology

Volumn 85, Issue 4, 2006, Pages 257-262

  Park, Y H ^a   Lee, J J ^b   Ryu, M H ^c   Kim, S Y ^d   Kim, D H ^e   Do, Y R ^f   Lee, K H ^g   Oh, S J ^h   Kim, Y K ^c   Suh, C W ^c   Heo, D S ^d   Ryoo, B Y ^a   Kim, J K ^e   Song, H S ^f   Lee, W S ⁱ   Kim, H J ^b   Bang, Y J ^d   Yang, S H ^a   Sohn, S K ^e   Kang, Y K ^c  

^a Korea Cancer Center Hospital   (South Korea)

^b Chonnam National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Kyungpook National University   (South Korea)

^f Keimyung University   (South Korea)

^g Yeungnam University   (South Korea)

^h Sungkyunkwan University   (South Korea)

ⁱ Gyeongsang National University   (South Korea)

Author keywords

CHOP; DLBCL; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; KOREA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SALVAGE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KOREA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDNISONE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33644514936     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0060-6     Document Type: Article

References (23)

1. Chang KL, Arber DA, Weiss LM (1996) CD20: A review. Appl Immunohistochem 4:1-15
2. Cheson BD (2005) What is new in lymphoma? Cancer J Clin 54:260-272
3. Coiffier B (2005) Current strategies for the treatment of diffuse large B cell lymphoma. Curr Opin Hematol 12:259-265
4. Demidem A, Hanna N, Hariharan H et al (1995) Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins. FASEB J 9:A206
5. Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126
6. Fisher RI, Gaynor ER, Dahlberg S et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherpay regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
7. Fisher RI, Miller TP, and O'Connor OA (2004) Diffuse aggressive lymphoma. Hematology 221-236
8. Foran JM, Rochatiner AZS, Conningham et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324
9. Gordon LI, Harrington D, Andersen J et al (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349
10. Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin's lymphoma: An update. Lancet Oncol 5:341-353
11. Jaffe ES, Harris NL, Stein H et al (2001) Tumours of haematopoietic and lymphoid tissue in World Health Organization Classification of Tumors. IARC Press, Lyon, pp 171-174
12. Kang YK, Kim BS, Kim TW et al (1999) Clinicopathologic characteristics of Korean non-Hodgkin's lymphomas based on REAL classification. J Korean Cancer Assoc 31:641-652
13. Ko YH, Kim CW, Park CS et al (1998) REAL classification of malignant lymphoma in the Republic of Korea. Cancer 83:806-812
14. Lee SS, Cho KJ, Kim CW, Kang YK (1999) Clinicopathological analysis of 501 non-Hodgkin's lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms. Histopathology 35:345-354
15. McLaughlin P, Grillo-Lopez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
16. Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284
17. Pfreundschuh MG, Trumper L, Ma D et al (2004) Randomized intergroup trial of first line treatment for patients <60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - Early stopping after the first interim analysis. J Clin Oncol 22:14S (abstract no. 6500)
18. Reff ME, Carner K, Chambers KS, Chinn PC et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
19. Sehn LH, Donaldson J, Chhanabhai M et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033
20. Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652
21. Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821-830
22. Vose JM, Link BK, Grossbard ML et al (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397
23. Wohrer S, Puspok A, Drach J et al (2004) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 15:1086-1090